Benefits of using multiple first-line therapies against malaria
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Despite the availability of many drugs and therapies to treat malaria, many countries' national policies recommend using a single first-line therapy for most clinical malaria cases. To assess whether this is the best strategy for the population as a whole, we designed an evolutionary-epidemiological modeling framework for malaria and compared the benefits of different treatment strategies in the context of resistance evolution. Our results show that the population-wide use of multiple first-line therapies (MFT) against malaria yields a better clinical outcome than using a single therapy or a cycling strategy where therapies are rotated, either on a fixed cycling schedule or when resistance levels or treatment failure become too high. MFT strategies also delay the emergence and slow the fixation of resistant strains (phenotypes), and they allow a larger fraction of the population to be treated without trading off future treatment of cases that may be untreatable because of high resistance levels. Earlier papers have noted that cycling strategies have the disadvantage of creating a less temporally variable environment than MFT strategies, making resistance evolution easier for the parasite. Here, we illustrate a second feature of parasite ecology that impairs the performance of cycling policies, namely, that cycling policies degrade the mean fitness of the parasite population more quickly than MFT policies, making it easier for new resistant types to invade and spread. The clinical benefits of using multiple first-line therapies against malaria suggest that MFT policies should play a key role in malaria elimination and control programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious Diseases of Humans: Dynamics and Control
Anderson, R. M., & May, R. M. (1991) · doi:10.1093/oso/9780198545996.001.0001 · Cited by 6,179
Qinghaosu (Artemisinin): The Price of Success
White, N. J. (2008) · Science · doi:10.1126/science.1155165 · Cited by 954 · cited 2×
“Extensive resistance has yet to be detected to artemisinin drugs, but there is concern that resistance could emerge and spread rapidly (4).”
The entomological inoculation rate and Plasmodium falciparum infection in African children
Smith, D. L., Dushoff, J., Snow, R. W., & Hay, S. I. (2005) · Nature · doi:10.1038/nature04024 · Cited by 369 · cited 1×
“Untreated asymptomatic infections are cleared in 200 days on average for sensitive strains (30, 31) and more quickly for resistant strains,dependingonhowcostlyresistanceistotheparasite;clinical episodeslastafewdaystoafewweeks,dependingontheeffec-Fig tiveness of drug treatment (30).”
Self-citation
Cited by
Access to effective antimicrobials: a worldwide challenge
Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00474-2 · Cited by 1,465
Self-citationArtemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L., Nguon, C., Day, N. P. J., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2331 · Cited by 645
Malaria eradication within a generation: ambitious, achievable, and necessary
Feachem, R. G. A., Chen, I., Akbari, O., Bertozzi-Villa, A., Bhatt, S., Binka, F., Boni, M. F., Buckee, C., Dieleman, J., Dondorp, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31139-0 · Cited by 366
Self-citationDrug‐resistant malaria: Molecular mechanisms and implications for public health
Petersen, I., Eastman, R., & Lanzer, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.042 · Cited by 289
A Research Agenda for Malaria Eradication: Drugs
The malERA Consultative Group on Drugs (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000402 · Cited by 288
Metadata
- Authors
- Boni, M. F., Smith, D. L., & Laxminarayan, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-09-16
- Volume
- 105
- Issue
- 37
- Pages
- 14216-14221
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2030481162
- Cited by
- 157
- References
- 3
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits of using multiple first-line therapies against malaria. https://app.cochat.ai/papers/10.1073/pnas.0804628105
- The paper
- Boni, M. F., Smith, D. L., & Laxminarayan, R. (2008). Benefits of using multiple first-line therapies against malaria. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0804628105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.